Astria Therapeutics (ATXS) said Wednesday that navenibart, its potential hereditary angioedema treatment, has received Orphan Medicinal Product Designation from the European Commission.
The status provides incentives for the development of products for diagnosing, preventing or treating rare life-threatening or very serious conditions in the EU, according to the company.
Astria said that based on initial results from a phase 1b/2 clinical trial, navenibart showed a favorable safety and tolerability profile and reduced monthly attack rates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.